Buy Like Buffett
Watchlist

Flagship explainer

How RIGEL PHARMACEUTICALS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$294M · 100%Cost of revenue$19.6M · 7%Gross profit$275M · 93%Operating income$125M · 43%Income before tax$122M · 41%Income tax−$245M · −83%Net income$367M · 125%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$294M100%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
Cost of revenue$19.6M7%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
$275M93%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
$125M43%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
Income before tax$122M41%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
Income tax−$245M−83%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
$367M125%
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001034842-26-000015 · filed Mar 3, 2026
· event Dec 31, 2025 · retrieved Sep 4, 2026 · annual-row source set
Embed this chart

View the full RIGEL PHARMACEUTICALS, INC. analysis at Buy Like Buffett